Study Overview

The table below provides an overview on the cohort studies included in Adata(Viewer). It displays the number of recruited participants and key information on the respective study design. Additionally, links are provided which facilitate access to the underlying datasets.


Legend

Cohort Participants Healthy MCI Patients AD Patients 2+ visits Follow-up Interval Location Diagnostic Criteria Reference Data Access
A4
6943 6943 0 0 0 ~8 USA, Canada, Australia Amyloid positive, cog. healthy DOI Apply
ABVIB
280 not reported not reported not reported 227 12 USA not reported DOI Apply
ADNI
2249 813 1016 389 1978 6 USA, Canada NINCDS-ADRDA DOI Apply
AIBL
1378 803 134 181 1019 18 Australia NINCDS-ADRDA DOI Shared through consortium
ANM
1702 793 397 512 1254 12 Europe NINCDS-ADRDA DOI Apply
ARWIBO
2617 1476 208 281 80 12 Italy NINCDS-ADRDA DOI Apply
DOD-ADNI
458 181 27 0 458 12 USA, Canada SFVAMC DOI Apply
EDSD
474 183 140 151 0 no follow-up Europe NINCDS-ADRCA DOI Apply
EMIF
1221 386 526 201 0 no follow-up Europe NINCDS-ADRDA DOI Shared through consortium
EPAD
2096 2071 not reported 14 1596 12 Europe NINCDS-ADRDA DOI Apply
I-ADNI
262 2 54 187 0 no follow-up Italy NINCDS-ADRDA DOI Apply
JADNI
537 151 233 149 518 6 Japan NINCDS-ADRDA DOI Apply
NACC
40858 15894 3649 11761 27657 12 USA UDS Form D1 DOI Apply
OASIS
564 400 122 42 168 6 USA CDR DOI Apply
PREVENT-AD
348 348 0 0 334 12 Canada excluded MCI DOI Apply
PharmaCog
147 0 147 0 133 6 Europe aMCI with low A-beta 42 CSF levels DOI Apply
ROSMAP
3626 2514 898 203 3335 12 USA NINCDS-ADRDA DOI Apply
VASCULAR
250 144 106 0 0 no follow-up USA excluded AD DOI Apply
VITA
606 440 47 0 606 30 Austria NINCDS-ADRDA DOI Apply
WMH-AD
90 19 26 43 0 no follow-up Austria NINCDS-ADRDA DOI Apply